Training a neural network to collate data from several sources provides a high-resolution view of how people are moving around the world
go.nature.com/4omsyUl
Peptide injections are the hottest trend in wellness, but researchers say enthusiasm for these unregulated drugs has got ahead of the science.
go.nature.com/4xrwSWf
Nature research paper: A first-in-class pulsatile FXR agonist for bile-acid-related liver diseases
go.nature.com/4omsxQc
A phase 3 trial reported in Nature Medicine shows weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD). #medsky 🧪
Impact of Methicillin Resistance on Outcomes of Staphylococcus aureus Bacteremia at a U.S. Center, 2023–2024
✅ Just Accepted
https://bit.ly/4ek9UYC
Further unraveling the association between HIV, immune suppression, and cancer survival
✅ Just Accepted
🔗 https://bit.ly/4vGiXKk
Jacques Cornwell describes in Nature a seven-step framework to help bridge the gap from passively reading a research paper to actively analysing it. “Although there is no universal framework for pulling apart a dense primary paper, having a consistent method is crucial.” #Academicsky 🧪
Among US veterans with #HeartFailure with reduced ejection fraction, fewer than one-quarter achieved quadruple guideline-directed medical therapy within 2.9 years, and medication copays were associated with lower rates of therapy achievement. ja.ma/3Qk1Tuv
Nearly all systemic antifungal clinical trial sites in the US are metropolitan, with just 0.6% of rural residents living within 30 miles of a treatment trial site.
ja.ma/4uB4a2L
Linafexor is a rapidly cleared FXR agonist designed to mimic natural bile acid signalling, achieving transient receptor activation with strong efficacy and reduced toxicity in preclinical and early clinical studies.
In a contemporary academic cohort of adults with Staphylococcus aureus bacteremia, methicillin resistance was associated with distinct epidemiologic charac
As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
Induction of β-Defensin 1 (DEFB1) via synthetic mRNA reduces Cryptosporidium parvum infection in human intestinal cells
✅ Just Accepted
🔗 https://bit.ly/3PZzE4t
